Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
Watch Drs. Jonathan Kay, Edward Li, and Andrew D. Zelenetz lead expert discussions on biologics and biosimilars. This curriculum has been developed to help prepare clinicians for the entry of biosimilars into clinical practice in order to make effective treatment decisions and communicate with patients about these new treatment options.
This site uses cookies. By continuing to use this website, you agree to their use. For details, please check our Privacy Policy.